“I think all too often we underestimate the impact of a cancer diagnosis on the mental health and well-being of the individual, thus it goes unaddressed.” ~Stephanie Zimmerman, MSN Receiving a diagnosis of cancer can bring on feelings of worry, fear, dread, anger, uncertainty and loss. Research indicates that, for some people, these symptoms of...
Read MoreIn a nutshell This study aimed to compare unrelated donor umbilical cord blood transplant and unrelated hematopoietic stem cell transplant in adult and pediatric patients with acute myeloid leukemia and acute lymphoblastic leukemia. This study concluded that unrelated donor umbilical cord blood transplants could be used more often as a treatment...
Read More
Video information: Which additional CLL treatment options are available for patients who develop resistance to ibrutinib (Imbruvica)? In this “Ask the Expert” session, Dr. Michael Keating, a leading CLL expert from The University of Texas MD Anderson Cancer Center, explains alternative inhibitor approaches if a patient becomes resistant....
Read More
In a nutshell This study reviewed evidence on venetoclax (Venclexta) for previously treated chronic lymphocytic leukemia (CLL). Some background Targeted therapy is the standard treatment of CLL. This includes the BCL2 inhibitor therapy venetoclax. BCL2 inhibitor therapy blocks a protein called BCL2 involved in leukemia cell growth. Venetoclax has...
Read More
In a nutshell This study reviewed evidence of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML). Some background CML is a disease in which the bone marrow makes too many mature and immature white blood cells. Most patients are diagnosed in the chronic (early) phase. Over recent years, targeted therapy with tyrosine...
Read More
In a nutshell This study examined treatment outcomes with dasatinib (Sprycel) for chronic myeloid leukemia (CML). Researchers reported a fast and strong treatment response to first-line dasatinib, particularly in older patients. The levels of a genetic mutation known as BCR-ABL1 at 3 months was found to be a predictor of treatment response. Some...
Read More
In a nutshell This review aimed to discuss the treatment options for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. This review concluded that chemotherapy combined with tyrosine kinase inhibitors is a good option for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Some background...
Read More
In a nutshell This study reviewed the occurrence and management of tumor lysis syndrome in patients receiving treatment for chronic lymphocytic leukemia (CLL). Some background Tumor lysis syndrome (TLS) is an uncommon but potentially life-threatening complication associated with the treatment of some cancers. TLS occurs when a large number of...
Read More
In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy. Some background Men are more likely to develop CLL than women....
Read More
In July 2017, the American Society of Clinical Oncology (ASCO) conducted the National Cancer Opinion Survey to find out what people in the US know about cancer. ASCO released the results in October. The findings have already influenced recommendations made by the organization. Beliefs About Cancer Risk Among other questions, the survey asked 4,016...
Read More
In a nutshell This study aimed to investigate if sorafenib (Nexavar) would be a useful maintenance therapy for acute myeloid leukemia patients who have received a stem cell transplant. This study concluded that sorafenib is useful as a maintenance therapy in these patients. Some background Acute myeloid leukemia (AML) occurs when abnormal...
Read MoreIn a nutshell This study aimed to investigate if clinical trials provide benefit for teens and young adults with acute lymphoblastic leukemia. This study concluded that teens and young adults with acute lymphoblastic leukemia who participated in clinical trials benefit from them. Some background Acute lymphoblastic leukemia (ALL) occurs...
Read More
